SciFi Futures
← Capabilities
Biotech & Medicine/Component technology

Systemic delivery of agents across the blood-brain barrier

Getting genes, drugs or devices from the bloodstream into brain cells at useful dose, brain-wide, after a simple injection.

State of the art

BI-hTFR1 capsid crosses human brain endothelium in vitro and transduces CNS of human-TFRC knock-in mice ~40-50x better than AAV9 (Science 2024); focused-ultrasound BBB opening used clinically in small trials.

What’s blocking it
  • Receptor targeting is species-specific; capsids binding human TfR1 often fail in macaque
  • Pre-existing anti-AAV immunity excludes a large fraction of patients and blocks redosing
  • Dose needed for brain-wide coverage drives liver toxicity and manufacturing cost

Who’s working on it

  • Benjamin DevermanResearcher
    Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard

    Engineered BI-hTFR1, an AAV9 capsid reprogrammed to bind human transferrin receptor, giving 40-50x more CNS expression than AAV9 in human TFRC knock-in mice (Science, 2024)

  • Its TransportVehicle platform produced AVLAYAH (tividenofusp alfa), approved by the FDA in March 2026 as the first biologic specifically designed to cross the blood-brain barrier

  • Used its TRACER platform to find cross-species BBB-penetrant capsids and identified ALPL as the receptor they use; VCAP-102 gave 20-400x more brain gene transfer than AAV9 in primates (2025)

  • Sangamo TherapeuticsCompany

    Reported its STAC-BBB capsid achieving widespread brain transduction after intravenous dosing in non-human primates at clinically relevant doses (2024)

  • Hong ChenResearcher
    Washington University in St. Louis

    Develops focused-ultrasound BBB opening, sonobiopsy and intranasal FUS delivery, the leading physical alternative to engineered carriers, now in small clinical studies

  • Philanthropic funder that has underwritten most early clinical trials of focused-ultrasound BBB opening for brain tumours and neurodegeneration

What to invest in

KindInvestmentScale
researchDirected-evolution and design campaigns for capsids and shuttle peptides validated in nonhuman primates, not just humanized mice$$$ $100M – $1B
engineeringManufacturing capacity for 1e16-plus vector genome doses at clinical purity$$$ $100M – $1B

Sci-fi concepts in reach

Cortical stack (continuous mind backup)indirectDream recording and directed dreamingindirectIntelligence amplification treatmentdirectCommercial memory implantsdirectMind uploading (software people)indirectNeural laceindirectDrug-delivered brain-to-brain networkdirectNexus-6 androids (replicants)indirectSimstim (recorded full-sensory experience)indirectResleeving (transferring a mind into a new body)indirectSelf-replicating von Neumann probeindirect

Sources